Results 111 to 120 of about 56,246 (219)

The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta‐Analysis

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6874-6887, August 2026.
ABSTRACT Aims Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Wan Chin Hsieh   +2 more
wiley   +1 more source

Trends in Second‐Line Initiations and Treatment Outcomes Across Age and Frailty Groups in People With Type 2 Diabetes: UK Population‐Based Study, 2019–2024

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7471-7482, August 2026.
ABSTRACT Aims To assess contemporary UK trends in second‐line treatment initiations and outcomes across age‐and‐frailty groups in people with type 2 diabetes (T2D). Materials and Methods We studied 117 046 UK adults with T2D initiating second‐line therapy between 2019–2024 (Clinical Practice Research Datalink).
M. M. Dinsdale   +11 more
wiley   +1 more source

A Case Report of Myocardial Infarction Complicated With Blood Pressure Fluctuations Caused by Pheochromocytoma

open access: yesThe Journal of Clinical Hypertension, Volume 28, Issue 8, August 2026.
ABSTRACT Pheochromocytoma typically presents with sustained or paroxysmal hypertension, but initial manifestation as acute non‐ST‐segment elevation myocardial infarction (NSTEMI) is rare. Peri‐procedural hemodynamic fluctuations are often dramatic, making diagnosis and management challenging.
HuiPing Li   +5 more
wiley   +1 more source

Effects of Xuefu Zhuyu oral liquid as adjunctive treatment for stable angina: a randomized controlled trial. [PDF]

open access: yesFront Med (Lausanne)
Cao W   +12 more
europepmc   +1 more source

Dapagliflozin does not impair microvascular hemorheology in type 2 diabetes mellitus: A multicenter randomized controlled trial (D‐PATH study)

open access: yesJournal of Diabetes Investigation, Volume 17, Issue 8, Page 1322-1334, August 2026.
Graphical abstract illustrating the study design, physiological rationale, and key findings of the D‐PATH trial. Dapagliflozin, an SGLT2 inhibitor, lowers HbA1c and body weight while increasing hematocrit and erythropoietin levels. Although an elevated hematocrit could theoretically increase blood viscosity and impair microcirculatory flow, ex vivo ...
Yuki Nakatani   +16 more
wiley   +1 more source

The changing epidemiology of human type 2 diabetes–associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities

open access: yesJournal of Internal Medicine, Volume 300, Issue 2, Page 131-152, August 2026.
Abstract Type 2 diabetes (T2D) is a major global health concern strongly associated with atherosclerosis and subsequent macrovascular complications. These complications are the leading cause of death among T2D patients. Despite a decline in cardiovascular events over the last decade, individuals with T2D still have an approximately doubled risk ...
Dania Al‐Sharify   +2 more
wiley   +1 more source

Long‐term association of physical activity with survival by primary cancer treatment in endometrial cancer: The Alberta Endometrial Cancer Cohort Study

open access: yesInternational Journal of Cancer, Volume 159, Issue 2, Page 345-358, 15 July 2026.
What's new? Accumulating evidence suggests a beneficial role of physical activity in cancer. However, it is unclear whether associations between physical activity and cancer outcomes vary by cancer treatment. Based on more than 16 years of follow‐up data from a cohort of endometrial cancer survivors, this study reveals that associations between ...
Minsuk Oh   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy